174 related articles for article (PubMed ID: 35049189)
21. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone.
Xie de R; Liang HL; Wang Y; Guo SS
Chin J Dig Dis; 2006; 7(1):49-54. PubMed ID: 16412038
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials.
Jin J; Teng C; Li T
Drug Des Devel Ther; 2018; 12():475-480. PubMed ID: 29563772
[TBL] [Abstract][Full Text] [Related]
25. S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.
Zhong S; Qie S; Yang L; Yan Q; Ge L; Wang Z
Medicine (Baltimore); 2017 Jul; 96(30):e7611. PubMed ID: 28746215
[TBL] [Abstract][Full Text] [Related]
26. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract][Full Text] [Related]
27. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Cunningham D; Chau I; Stocken DD; Valle JW; Smith D; Steward W; Harper PG; Dunn J; Tudur-Smith C; West J; Falk S; Crellin A; Adab F; Thompson J; Leonard P; Ostrowski J; Eatock M; Scheithauer W; Herrmann R; Neoptolemos JP
J Clin Oncol; 2009 Nov; 27(33):5513-8. PubMed ID: 19858379
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic Cancer Survival Increases with Chemo Combo.
Cancer Discov; 2016 Aug; 6(8):OF3. PubMed ID: 27363975
[TBL] [Abstract][Full Text] [Related]
29. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Barni S
Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):124-31. PubMed ID: 25865683
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
31. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Scheithauer W; Schüll B; Ulrich-Pur H; Schmid K; Raderer M; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Kornek GV
Ann Oncol; 2003 Jan; 14(1):97-104. PubMed ID: 12488300
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials.
Feng Z; Yan P; Hou X; Feng J; He X; Yang K
Ann Palliat Med; 2020 May; 9(3):883-894. PubMed ID: 32389017
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Courtin A; Richards FM; Bapiro TE; Bramhall JL; Neesse A; Cook N; Krippendorff BF; Tuveson DA; Jodrell DI
PLoS One; 2013; 8(6):e67330. PubMed ID: 23840665
[TBL] [Abstract][Full Text] [Related]
34. Real-world outcomes of adjuvant gemcitabine
Kang S; Yoo C; Lee SH; Oh D; Song TJ; Lee SS; Jeong JH; Park DH; Seo DW; Park JH; Hwang DW; Song KB; Lee JH; Lee W; Kwak BJ; Hong S; Chang HM; Ryoo BY; Kim KP; Kim SC
Ther Adv Med Oncol; 2022; 14():17588359221097190. PubMed ID: 35571606
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.
Bria E; Milella M; Gelibter A; Cuppone F; Pino MS; Ruggeri EM; Carlini P; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
Cancer; 2007 Aug; 110(3):525-33. PubMed ID: 17577216
[TBL] [Abstract][Full Text] [Related]
36. Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
Dig Liver Dis; 2014 May; 46(5):452-9. PubMed ID: 24565950
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis.
Lu S; Zhang Y; Zhou X; Zhou D; Yang Q; Ju B; Zhao X; Hu Z; Xie H; Zhou L; Zheng S; Wang W
Sci Rep; 2016 Nov; 6():36944. PubMed ID: 27833144
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of gemcitabine and cisplatin combination chemotherapy versus gemcitabine alone for pancreatic cancer.
Huang D; Fang J; Luo G
J Cancer Res Ther; 2016 Oct; 12(Supplement):104-108. PubMed ID: 27721265
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer.
Eltawil KM; Renfrew PD; Molinari M
HPB (Oxford); 2012 Apr; 14(4):260-8. PubMed ID: 22404265
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
